{"entity":{"id":"nct06941857","kind":"trial","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin), fOLFIRI (5-FU, leucovorin, irinotecan), leucovorin (folinic acid), fluorouracil (5-FU) and other drugs in pancreatic cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.","summary":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT06941857 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 20 participants, started 2025-09-04 and due to reach its primary completion in 2028-12. Interventions recorded: Oxaliplatin; Irinotecan; Folinic Acid; 5-Fluorouracil (5-FU); NC410; Nivolumab; Ipilimumab. Conditions listed: Pancreatic Cancer. Primary outcome: Number of participants experiencing unexpected toxicities. Unexpected toxicities are toxicities related to the study drug required treatment discontinuation.. Pancreatic eligibility wording from the registry: \"* Metastatic histologically or cytologically confirmed pancreatic ductal adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06941857","url":"https://clinicaltrials.gov/study/NCT06941857"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["capox","folfiri","leucovorin","fluorouracil","nivolumab","ipilimumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06941857","phase":"2","setting":"A Phase 2 Study of NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Treatment-naïve, Metastatic Pancreatic Cancer","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06941857/","neighbours":{"cancer":[{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfiri","kind":"drug","name":"FOLFIRI (5-FU, leucovorin, irinotecan)","route":"/drugs/folfiri/"},{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"leucovorin","kind":"drug","name":"Leucovorin (folinic acid)","route":"/drugs/leucovorin/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}